{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:59:55Z","timestamp":1790049595736,"version":"4.0.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00487","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T09:04:26Z","timestamp":1563527066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Claudia","family":"Siebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Ciato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Frei-Stuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gustavo","family":"Perez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Monteserin-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel K.","family":"Walch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm R.","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Korpershoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter K.","family":"Stalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage Iii-Iv adrenocortical carcinomas (Acc): an European network for the study of adrenal tumor (Ensat) study","volume":"26","author":"Libe","year":"2015","journal-title":"Ann Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","journal-title":"Nat Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccell.2016.07.013","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"30","author":"Zheng","year":"2016","journal-title":"Cancer Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (Osi-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/a-0715-1946","article-title":"Advanced adrenocortical carcinoma - what to do when first-line therapy fails?","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1432-1033.1994.tb19910.x","article-title":"Heat-shock proteins as molecular chaperones","volume":"219","author":"Becker","year":"1994","journal-title":"Eur J Biochem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0163-7258(98)00013-8","article-title":"The 90-Kda molecular chaperone family: structure, function, and clinical applications. A comprehensive review","volume":"79","author":"Csermely","year":"1998","journal-title":"Pharmacol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1128\/MCB.00649-09","article-title":"Nuclear import of the glucocorticoid receptor- HSP90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta","volume":"29","author":"Echeverria","year":"2009","journal-title":"Mol Cell Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1074\/jbc.M109200200","article-title":"The role of HSP90n, a new member of the HSP90 family, in signal transduction and neoplastic transformation","volume":"277","author":"Grammatikakis","year":"2002","journal-title":"J Biol Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0014-5793(04)00229-7","article-title":"HSP90 isoforms: functions, expression and clinical importance","volume":"562","author":"Sreedhar","year":"2004","journal-title":"Febs Lett."},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/toxsci\/69.1.183","article-title":"HSP90alpha, HSP90beta, and P53 expression following in vitro hyperthermia exposure in gestation day 10 rat embryos","volume":"69","author":"Dugyala","year":"2002","journal-title":"Toxicol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1111\/j.1742-4658.2007.05974.x","article-title":"Expressed as the sole HSP90 of yeast, the alpha and beta isoforms of human HSP90 differ with regard to their capacities for activation of certain client proteins, whereas only HSP90beta generates sensitivity to the HSP90 inhibitor radicicol","volume":"274","author":"Millson","year":"2007","journal-title":"Febs J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/dbio.1999.9262","article-title":"Disruption of zebrafish somite development by pharmacologic inhibition Of HSP90","volume":"210","author":"Lele","year":"1999","journal-title":"Dev Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1290\/1071-2690(2000)036<0139:FOKHSP>2.0.CO;2","article-title":"Function Of 90-Kda heat shock protein in cellular differentiation of human embryonal carcinoma cells","volume":"36","author":"Yamada","year":"2000","journal-title":"In Vitro Cell Dev Biol Anim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mrd.1080280302","article-title":"Stage and lineage-regulated expression of two HSP90 transcripts during mouse germ cell differentiation and embryogenesis","volume":"28","author":"Gruppi","year":"1991","journal-title":"Mol Reprod Dev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00429-002-0258-5","article-title":"Heat shock protein Hsp86 expression during mouse embryo development, especially in the germ-line","volume":"205","author":"Vanmuylder","year":"2002","journal-title":"Anat Embryol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dev.127.1.1","article-title":"Mice lacking HSP90beta fail to develop a placental labyrinth","volume":"127","author":"Voss","year":"2000","journal-title":"Development."},{"key":"B20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0014-5793(99)01070-4","article-title":"The beta-isoform of heat shock protein Hsp-90 is structurally related with human microtubule-interacting protein mip-90","volume":"457","author":"Cambiazo","year":"1999","journal-title":"Febs Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/128_2012_356","article-title":"HSP90: structure and function","volume":"328","author":"Jackson","year":"2013","journal-title":"Top Curr Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1021\/jm980403y","article-title":"Structural basis for inhibition of the HSP90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin","volume":"42","author":"Roe","year":"1999","journal-title":"J Med Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0092-8674(00)80203-2","article-title":"Crystal structure of an HSP90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent","volume":"89","author":"Stebbins","year":"1997","journal-title":"Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S1097-2765(03)00065-0","article-title":"Structural and functional analysis of the middle segment of HSP90: implications for ATP hydrolysis and client protein and cochaperone interactions","volume":"11","author":"Meyer","year":"2003","journal-title":"Mol Cell."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8385","DOI":"10.1128\/MCB.02188-05","article-title":"The middle domain of HSP90 acts as a discriminator between different types of client proteins","volume":"26","author":"Hawle","year":"2006","journal-title":"Mol Cell Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.molcel.2006.12.008","article-title":"An acetylation site in the middle domain of HSP90 regulates chaperone function","volume":"25","author":"Scroggins","year":"2007","journal-title":"Mol Cell."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.str.2004.03.020","article-title":"The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli HSP90, reveals a potential substrate binding site","volume":"12","author":"Harris","year":"2004","journal-title":"Structure."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17757","DOI":"10.1074\/jbc.M800540200","article-title":"Conserved conformational changes in the atpase cycle of human HSP90","volume":"283","author":"Richter","year":"2008","journal-title":"J Biol Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/embor.2009.153","article-title":"HSP90 is regulated by a switch point in the C-terminal domain","volume":"10","author":"Retzlaff","year":"2009","journal-title":"Embo Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1006\/jmbi.2000.4157","article-title":"C-Terminal regions of HSP90 are important for trapping the nucleotide during the atpase cycle","volume":"303","author":"Weikl","year":"2000","journal-title":"J Mol Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1379\/1466-1268(1998)003<0100:arbttn>2.3.co;2","article-title":"Antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamycin","volume":"3","author":"Schulte","year":"1998","journal-title":"Cell Stress Chaperones."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/sj.onc.1201790","article-title":"Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol","volume":"16","author":"Sharma","year":"1998","journal-title":"Oncogene."},{"key":"B33","doi-asserted-by":"publisher","first-page":"22796","DOI":"10.1074\/jbc.271.37.22796","article-title":"Polyubiquitination and proteasomal degradation of the P185c-Erbb-2 receptor protein-tyrosine kinase induced by geldanamycin","volume":"271","author":"Mimnaugh","year":"1996","journal-title":"J Biol Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"14536","DOI":"10.1073\/pnas.93.25.14536","article-title":"Pharmacologic shifting of a balance between protein refolding and degradation mediated by HSP90","volume":"93","author":"Schneider","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"HSP90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10637-015-0246-2","article-title":"Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a mayo clinic phase II consortium study","volume":"33","author":"Pedersen","year":"2015","journal-title":"Invest New Drugs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cbdd.13486","article-title":"Spotlight on 17-AAG as an HSP90 inhibitor for molecular targeted cancer treatment","volume":"93","author":"Talaei","year":"2019","journal-title":"Chem Biol Drug Des."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.2174\/092986708786242895","article-title":"Novobiocin And Additional Inhibitors Of The HSP90 C-Terminal Nucleotide-Binding Pocket","volume":"15","author":"Donnelly","year":"2008","journal-title":"Curr Med Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of cushing disease","volume":"21","author":"Riebold","year":"2015","journal-title":"Nat Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","article-title":"Nvp-Auy922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis","volume":"68","author":"Eccles","year":"2008","journal-title":"Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: translating preclinical hypotheses into clinical promise","volume":"74","author":"Proia","year":"2014","journal-title":"Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1093\/annonc\/mdy336","article-title":"Activity of the HSP90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","volume":"29","author":"Piotrowska","year":"2018","journal-title":"Ann Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"17239","DOI":"10.1038\/s41598-018-35417-0","article-title":"High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer","volume":"8","author":"Jansson","year":"2018","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: european society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1530\/ERC-13-0429","article-title":"Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia","volume":"21","author":"Papathomas","year":"2014","journal-title":"Endocr Relat Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2015.12.009","article-title":"TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors","volume":"423","author":"Hantel","year":"2016","journal-title":"Mol Cell Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"79292","DOI":"10.18632\/oncotarget.12685","article-title":"Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation","volume":"7","author":"Hantel","year":"2016","journal-title":"Oncotarget."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00418-014-1258-2","article-title":"Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma","volume":"143","author":"Feuchtinger","year":"2015","journal-title":"Histochem Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"Synergyfinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics."},{"key":"B51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12672-016-0251-8","article-title":"HSP90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer","volume":"7","author":"Agyeman","year":"2016","journal-title":"Horm Cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"E1978","DOI":"10.3390\/ijms18091978","article-title":"Targeting heat shock proteins in cancer: a promising therapeutic approach","volume":"18","author":"Chatterjee","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mce.2018.10.009","article-title":"HSP90 inhibition in adrenocortical carcinoma: limited drug synergism with mitotane","volume":"480","author":"Sbiera","year":"2019","journal-title":"Mol Cell Endocrinol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/ijc.24825","article-title":"Biib021, a synthetic HSP90 inhibitor, has broad application against tumors with acquired multidrug resistance","volume":"126","author":"Zhang","year":"2010","journal-title":"Int J Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1158\/1078-0432.CCR-11-0562","article-title":"The novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous kit mutations","volume":"17","author":"Floris","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"Vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society Of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg."},{"key":"B58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-61779-295-3_3","article-title":"HSP90 and client protein maturation","volume":"787","author":"Wayne","year":"2011","journal-title":"Methods Mol Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/OTT.S65804","article-title":"Ganetespib: research and clinical development","volume":"8","author":"Jhaveri","year":"2015","journal-title":"Onco Targets Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1158\/1535-7163.MCT-12-0615","article-title":"Targeting KRAS-mutant non-small cell lung cancer with the HSP90 inhibitor ganetespib","volume":"11","author":"Acquaviva","year":"2012","journal-title":"Mol Cancer Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000314280","article-title":"Role of the mTOR pathway in normal and tumoral adrenal cells","volume":"92","author":"De Martino","year":"2010","journal-title":"Neuroendocrinology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/jcb.27451","article-title":"MAPK\/ERK pathway inhibition is a promising treatment target for adrenocortical tumors","volume":"120","author":"Pereira","year":"2019","journal-title":"J Cell Biochem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1530\/ERC-17-0447","article-title":"Development of new preclinical models to advance adrenocortical carcinoma research","volume":"25","author":"Kiseljak-Vassiliades","year":"2018","journal-title":"Endocr Relat Cancer."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T06:46:30Z","timestamp":1664001990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":63,"alternative-id":["10.3389\/fendo.2019.00487"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00487","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"article-number":"487"}}